Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling

Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody

(2013) M Reilly et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

(2013) Stephanie M Pyonteck et al.   NATURE MEDICINE

Toll-like receptor 2 mediates microglia/brain macrophage MT1-MMP expression and glioma expansion

(2013) K. Vinnakota et al.   NEURO-ONCOLOGY

Tumor-Produced Versican V1 Enhances hCAP18/LL-37 Expression in Macrophages through Activation of TLR2 and Vitamin D3 Signaling to Promote Ovarian Cancer Progression In Vitro

(2013) Dong Li et al.   PLoS One

Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation

(2012) Winnie W. Pong et al.   ANNALS OF NEUROLOGY

STAT3-Driven Upregulation of TLR2 Promotes Gastric Tumorigenesis Independent of Tumor Inflammation

(2012) Hazel Tye et al.   CANCER CELL

Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression

(2011) D.S. Markovic et al.   BRAIN BEHAVIOR AND IMMUNITY

Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury

(2011) Conrad A. Farrar et al.   FASEB JOURNAL

The brain tumor microenvironment

(2011) Nikki A. Charles et al.   GLIA

Role of Versican, Hyaluronan and CD44 in Ovarian Cancer Metastasis

(2011) Miranda Ween et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Microglia/macrophages promote glioma progression

(2010) Haiyan Zhai et al.   GLIA

DAMPening Inflammation by Modulating TLR Signalling

(2010) A. M. Piccinini et al.   MEDIATORS OF INFLAMMATION

Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis

(2009) Sunhwa Kim et al.   NATURE

Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion

(2009) D. S. Markovic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression

(2009) James F Curtin et al.   PLOS MEDICINE

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY